Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the 7th most common cancer worldwide but is the 4th deadliest, because diagnosis tend to be late and current systemic therapies are poorly efficacious. Within the same tumour, different parts of the HCC can belong to separate molecular sub-groups. In addition, there is currently no validated predictive biomarkers to help clinicians select the best therapy for an individual patient. This challenge poses an urgent, unmet clinical need. To address this, the multi-disciplinary research program Precision Medicine in Liver Cancer across an Asia-Pacific Network (PLA

Trial Details

NCT ID
NCT05516628
Phase
PHASE2
Sponsor
National Cancer Centre, Singapore
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Surgical Resection
  • Adjuvant Atezolizumab-Bevacizumab Therapy
Locations (sample)
  • Singapore, Singapore|1.28967,103.85007
  • Singapore, Singapore|1.28967,103.85007
  • Singapore, Singapore|1.28967,103.85007
  • Singapore, Singapore|1.28967,103.85007
  • Singapore, Singapore|1.28967,103.85007

Key Eligibility Criteria

  • Patient is willing, able and mentally competent to provide written informed consent prior to any testing undertaken for this study protocol, includ…
  • Male and female patients, age 21 to 90 at the time of signature of the informed consent form.
  • Patient is able to comply with scheduled visits, assessments and other study procedures.
  • Patient diagnosed with HCC or its histological variants who has undergone a resection within 4-12 weeks prior to Day 1 of Cycle 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →